Background: PIK3CA mutations have been reported to be associated with resistance to therapy in HER2+ breast cancers. This study, therefore, became imperative to determine the expression pattern of this mutant protein together with ER, PR and KI67 in order to serve as a useful predictive tool in the management of HER2 breast cancers.Methods: A total of 53 archived formalin-fixed, paraffin-embedded HER2+ breast cancer tissue blocks from 2015 to 2019 were used for the study in NAUTH Nnewi. The selected blocks were sectioned and stained with haematoxylin and eosin staining techniques. HER2, ER and PR status confirmation as well as PIK3CA and KI67 protein expressions were evaluated using immunohistochemistry (Avidin-biotin complex method). PIK3CA and KI67 expressions in the tissue were scored based on proportion and intensity of immune-labelling using the semi-quantitative method.Result: The mean age of subjects was 47 years and the breast cancers were all invasive ductal carcinoma. Twenty-nine (54.7%) were ER+ while 24 (45.3%) were ER-. Twenty-one (39.6%) were PR+ while 32 (60.4%) were PR-. Twenty-one (39.6%) were PIK3CA negative, 9(35.8%) showed low PIK3CA, while 13(24.5%) showed high PIK3CA. Thirty-four (64.2%) were negative for KI67, 11(20.8%) showed low KI67, while 8(15.5%) showed high KI67. There was weak and moderate positive relationship between ER/PR status and PIK3CA (r=-0.032; p=0.822) and KI67 (r=0.050; p=0.721) respectively. A weak negative correlation between KI67 and PIK3CA (r=-0.118; p=0.401) were observed with 12 (22.4%) of the 13 highly positive PIK3CA cases showing either negative or low for KI67 immunoreactivity while 7(13.2%) of the 8 highly positive KI67 cases showed either negative or low PIK3CA immunoreactivity.Conclusion: This study established a moderate expression of PIK3CA mutant protein. It also pointed out an existing interesting relationship between PIK3CA and KI67, which can be further revealed in future studies.
Introduction HIV (human immunodeficiency virus)-associated immunodeficiency is the single most important acquired immunodeficiency in humans, underlying several diseases. The presence of HIV infection may be unsuspected or undetected in tissues due to latency or failure of the consulting physician to document it on the requisition form. HIV-1p24 protein is a component of the HIV particle capsid that can be exploited serologically and immunohistochemically to detect the presence of HIV infection. This study aimed to assess the usefulness of HIV-1 p24 immunohistochemistry in detecting the presence of HIV infection in histopathology tissues in a resource-challenged setting. Materials and Methods HIV-1p24 immunohistochemical expression was evaluated in 59 cases from the archives of both Nnamdi Azikiwe University Teaching Hospital (NAUTH) and Pathocon Specialist Clinic and Research Institute over a 10-year period. Pathology consult forms of all clinically and morphologically suspected cases of Kaposi sarcoma and their blocks were retrieved, recut, and reviewed using hematoxylin and eosin, and then subjected to HIV-1p24 immunohistochemical staining. Results Of the 59 cases, 38 expressed p24, whereas 21 were negative. Fifteen of the positive cases had no prior documented evidence of HIV infection. Five cases with clinically known statuses, four positive and one negative, were found to be negative and positive, respectively, following HIV-1p24 immunohistochemical staining, probably due to usage of ELISA (enzyme-linked immunosorbent assay) detection kit only and long term antiretroviral therapy. HIV infection was commoner in the third and fourth decades of life. Conclusion HIV-1p24 is a useful low-cost immunohistochemical marker in detecting the presence of HIV infection in histopathology specimens, even in previously unsuspected cases.
Albinism results from a deficiency of the protein responsible for melanin production in melanocytes. Albinos are at an increased risk of dermatoses and malignancies. Primary carcinosarcoma of the skin is an exceedingly rare biphasic tumor composed of malignant epithelial and mesenchymal elements with an unclear histogenesis. To our knowledge, this has not been reported in an African albino. Here, we report the index case of this rare tumor in an albino of African descent.
Aim: Dyspepsia is a term differently understood, and associated with various upper gastro-intestinal endoscopic and histopathologic patterns. Most patients have regarded upper abdominal pain as ‘peptic ulcer disease’ with resultant late presentation of upper gastro-intestinal malignancies in some cases. This study examined the clinical presentation, endoscopic and histopathological patterns among patients with dyspeptic symptoms in Nnewi, South-East Nigeria. Methods: This hospital based descriptive cross-sectional study examined 352 patients presenting with dyspepsia. Abdominal ultrasound was used to exclude patients with dyspepsia of biliary or pancreatic origin. An interviewer administered questionnaire (using the short form Leeds dyspepsia questionnaire) was used to describe dyspepsia patterns, and gastroscopy done on the included patients following an overnight fast. Samples obtained from endoscopy were assessed histologically for morphology and presence of H. pylori organism. Results: Most participants belonged to 55 to 74 years age group with a mean age of 52.27±2.59 years. Epigastric discomfort (96.9%), heart burn (63.1%) and belching (55.4%) were the commonest symptoms. The commonest endoscopy and histopathologic findings was chronic gastritis (63.06% and 51.99% respectively), although there was poor agreement between the two modalities. Conclusion: Histology remains the goal standard for diagnosis. However, we recommend endoscopy for dyspeptic patients especially in the elderly to enhance early detection of cancers, which were significant in this study.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.